Bls 1 frá 637 niðurstöður
TECHNICAL FIELD OF THE INVENTION
This invention relates to pharmaceutical compositions useful for treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration, and to methods for using the compositions.
BACKGROUND OF THE INVENTION
Neurotrophic factors exhibit a trophic effect
TECHNICAL FIELD
The present invention relates to nanoparticles that change their properties under hypoxic conditions, and thus can be used for the diagnosis and treatment of hypoxia-related diseases.
BACKGROUND ART
Hypoxia, a pathological condition deprived of adequate oxygen supply, is a hallmark
BACKGROUND OF THE INVENTION
This invention relates to methods for identifying compounds that modify transcriptional responses to hypoxia.
As solid tumors evolve from a single malignant cell into a multicellular mass, oxygen tension in the tumor microenvironment drops as the passive diffusional
FIELD OF THE INVENTION
Embodiments of the invention comprise methods of treating hypoxia and associated conditions. In particular, directional therapeutic angiogenesis induced in patients via a conditionally silenced vector expressing a desired factor.
BACKGROUND
Therapeutic angiogenesis is a
FIELD OF THE INVENTION
This invention relates to the field of molecular signaling and physiological responses to external stimuli. In particular, this invention provides nucleic acid molecules and proteins that constitute new members of the bHLH-PAS superfamily of transcription
FIELD OF THE INVENTION
This invention relates to the field of molecular signaling and physiological responses to external stimuli. In particular, this invention provides nucleic acid molecules and proteins that constitute new members of the bHLH-PAS superfamily of transcription
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention relates to a medical nuclear contrast medium, and more particularly to a nitroimidazole-amino acid hypoxia contrast medium, a precursor, preparation method, and use thereof.
2. Description of the Related Art
Tumors have become one
BACKGROUND OF THE INVENTION
1. Technical Field
The present invention relates to the identification of genes that are differentially expressed in hypoxia and use of the genes and gene products for diagnosis and therapeutic intervention. The invention further relates to identification of
BACKGROUND OF THE INVENTION
1. Technical Field
The present invention relates to the identification of genes that are differentially expressed in hypoxia and use of the genes and gene products for diagnosis and therapeutic intervention. The invention further relates to identification of
FIELD OF THE INVENTION
The present invention relates to compositions and methods for protecting neural tissue from anoxia and/or spreading depression. The present invention further relates to compositions and methods for mitigating side effects associated with pharmaceuticals that manipulate the
BACKGROUND OF THE INVENTION
Hypoxia inducible factor-1 (HIF-1) is a heterodimeric transcriptional activator that regulates the expression of genes involved in adaptation to hypoxic stress. HIF-1 is composed of two subunits referred to as HIF-1.alpha. and HIF-1.beta.. These subunits are expressly
BACKGROUND OF THE INVENTION
Many of the procedures presently conducted in the field of nuclear medicine involve radiopharmaceuticals which provide diagnostic images of bloo flow (perfusion) in the major organs and in tumors. The regional uptake of these radiopharmaceuticals within the organ of
BACKGROUND OF INVENTION
Many of the procedures presently conducted in the field of nuclear medicine involve radiopharmaceuticals which provide diagnostic images of blood flow (perfusion) in the major organs and in tumors. The regional uptake of these radiopharmaceuticals within the organ of interest
BACKGROUND OF THE INVENTION
Many of the procedures presently conducted in the field of nuclear medicine involve radiopharmaceuticals which provide diagnostic images of blood flow (perfusion) in the major organs and in tumors. The regional uptake of these radiopharmaceuticals within the organ of
BACKGROUND OF THE INVENTION
Many of the procedures presently conducted in the field of nuclear medicine involve radiopharmaceuticals which provide diagnostic images of blood flow (perfusion) in the major organs and in tumors. The regional uptake of these radiopharmaceuticals within the organ of